EGFR and colorectal carcinoma: For Stage IV CRC, regimens like FOLFOX, FOLFIRI, and FOLFOXIRI are often combined with monoclonal antibodies targeting EGFR or VEGF, such as cetuximab and bevacizumab, which have extended overall survival (OS) to over 24 months [7].